A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy

TY - JOUR

T1 - A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy

AU - Peruzzi, Mariangela

AU - De Luca, Leonardo

AU - Thomsen, Henrik S

AU - Romagnoli, Enrico

AU - D'Ascenzo, Fabrizio

AU - Mancone, Massimo

AU - Sardella, Gennaro

AU - Lucisano, Luigi

AU - Abbate, Antonio

AU - Frati, Giacomo

AU - Biondi-Zoccai, Giuseppe

PY - 2014

Y1 - 2014

N2 - Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.

AB - Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.

U2 - 10.1155/2014/213239

DO - 10.1155/2014/213239

M3 - Journal article

C2 - 25276771

SN - 1110-7243

VL - 2014

SP - 1

EP - 10

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

ER -